CD8A and type 1 diabetes mellitus: Among these models, the YES-RIP-hB7.1 mouse is expected to allow the characterization of hPPI-specific CD8+ and CD4+ hPPI epitopes on a major autoantigen targeted in T1D, including new epitopes, such as spliced or modified epitopes, in this proinflammatory context (70, 71).